Presentation is loading. Please wait.

Presentation is loading. Please wait.

Center for Studies of Addiction, University of Pennsylvania, USA

Published byScot Fowler Modified over 7 years ago

Similar presentations

Presentation on theme: "Center for Studies of Addiction, University of Pennsylvania, USA"— Presentation transcript:

1

2 Center for Studies of Addiction, University of Pennsylvania, USA
Integrated substance use disorder and HIV care in Vietnam: Effectiveness and cost Cecile Denis, PhD Center for Studies of Addiction, University of Pennsylvania, USA

3 Disclosures Project funded by NIDA grant R01- DA (C. P. O’Brien, MD, PhD, PI) AUG to JUL Buprenorphine/Naloxone (Suboxone®) was donated to the research by Indivior® (former Reckitt Benckiser®)

4 Vietnam 271,000 people using drugs (UNAIDS 2015)
14,000 new HIV infections in 2015, and most of them are driven by drug users 2006: Scale up of HIV prevention programs targeting people who inject drugs (PWID) (Giang et al., 2013) Sterile injection equipment, the introduction and expansion of methadone treatment, and increased access to antiretroviral therapy (Government of Vietnam, 2014) Although the proportion of HIV infections among PWID has declined from 30% in to 22% in 2013, PWID remain the largest risk group living with HIV infection (Vietnam Administration of HIV/AIDS Control, 2013)

5 Go Vap Integrated Treatment Clinic
Integrated Treatment provided A pharmacological opiate maintenance treatment with methadone (MET) or buprenorphine/naloxone (BUP/NX) Introduction of BUP/NX (Suboxone®) in January 2015 First time in Vietnam Counseling: 12 weekly sessions and 10 monthly sessions thereafter HIV screening and HIV treatment if needed HCV screening Structured and manual-based standardized counseling sessions Rooted in cognitive behavioral therapy Sessions assess the need for intervention in six areas of functioning: 1) Adherence to SUD, HIV, TB; 2) continued drug use and related drug and sex risk; 3) cravings for drug use; 4) psychological status (depression, anxiety, symptoms of psychiatric disorder); 5) confidence in and satisfaction with SUD treatment; and, 6) strategies for the next month Data recorded and available for review with the participant as a clinical tool to show progress and promote self-monitoring.

6 Participant characteristics (n=448)

7 Treatment retention High retention in treatment at 12 months (78.0%)
MET > BUP/NX MET: 89.9% BUP/NX: 57.0% Daily BUP/NX: 40.0% Thrice weekly BUP/NX: 69.8% Wilcoxon chi2= 110.9, p<0.0001

8 Change in heroin use Significant decrease of heroin use regardless of the treatment (F(12,277)=21.8, p<0.0001) BUP/NX > MET First 3 months of treatment (F(12,702)=0.69, p<0.0001)

9 HIV Prevalence 34.2% (n=153) Viral load CD4 count
Newly diagnosed 7.2% (n=11) Viral load Baseline range: 0-400,000 Reported ART adherence: 78% reported taking >90% of the time Suppressed viral load 82.8% at 6 months 90.5% at 12 months VL suppression was Not associated with the type of OMT neither the type of ART Linked to a better observance of ART (Pearson=7.18, p=0.007) and to the decrease of heroin use over 12 months (F(12,32)= 2.20, p=0.03) CD4 count Baseline Mean 326 (SD=202, range ), and >500 cells/mm3 = 37% 12-month < 350 cells/mm3 = 32% Not associated with the ART observance or the type of OMT

10 Cost of 6 months of integrated Tx program
Daily MET US$ (SD=160.21) < daily BUP/NX US$ (SD=480.36) Daily MET < BUP/NX thrice weekly US$ (SD=168.56) (F(2,122)=374.21, p<0.0001)

11 Conclusion Integrated treatment strategy showed significant positive impact on Drug use HIV detection Access to HIV care Integration of opiate maintenance treatment and HIV care in the same setting Not significantly increase the cost of the addiction treatment Decrease cost for HIV-positive participants by preventing them from having to travel to different locations However, still potential HIV reservoir that needs to be eliminated By improving the monitoring of treatment efficiency, and a better treatment adherence

12 PI: Charles O'Brien, MD, PhD - UPenn Co-PI:
Le Truong Giang, MD, PhD – HCMC, Vietnam Jean-Pierre Daulouède, MD, France Investigators David Metzger, PhD, UPenn, Marc Auriacombe, University of Bordeaux, France Gilles Raguin, MD, Expertise France Lisa Huang, MD, Expertise France Trung Nguyen, Expertise France, HCM Medical Univ. Vincent Trias, Expertise France Project director: Cecile Denis, UPenn Expertise France Research staff in HCMC Expertise France Staff in Vietnam Expertise France Staff in Paris, France Go Vap Center Staff in Ho Chi Minh City PAC Ho Chi Minh City Ministry of Health of Vietnam, Hanoi VAAC, Hanoi

Download ppt "Center for Studies of Addiction, University of Pennsylvania, USA"

Similar presentations

Washington D.C., USA, 22-27 July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County 2008-2010 Shoshanna Nakelsky, MPH Division of HIV and.

Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County Shoshanna Nakelsky, MPH Division of HIV and.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.

The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,

Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,
HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.

HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.
1 Situation of Current ARV Treatment in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Situation of Current ARV Treatment in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Expanded and Enhanced Treatment Services in a Los Angeles OTP Funded by The Center for Substance Abuse Treatment Targeted Capacity Expansion for Substance.

Expanded and Enhanced Treatment Services in a Los Angeles OTP Funded by The Center for Substance Abuse Treatment Targeted Capacity Expansion for Substance.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,

HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.

Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Www.aids2012.org Washington D.C., USA, JULY 22-27 2012 Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.

Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.

Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Copyright restrictions may apply Predictive Values of Psychiatric Symptoms for Internet Addiction in Adolescents: A 2-Year Prospective Study Ko C-H, Yen.

Copyright restrictions may apply Predictive Values of Psychiatric Symptoms for Internet Addiction in Adolescents: A 2-Year Prospective Study Ko C-H, Yen.
HIV-infected subjects with CD4 350 to 550 cells/mm 3 1763 serodiscordant couples HPTN 052 Study Design Immediate ART CD4 350-550 Delayed ART CD4

HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.

1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Positive Prevention for HIV+ Injection Drug Users Kelly Knight, Debra Allen, Caryn Pelegrino, Barbara Garcia and Jeff Moore.

Positive Prevention for HIV+ Injection Drug Users Kelly Knight, Debra Allen, Caryn Pelegrino, Barbara Garcia and Jeff Moore.
Drug Abuse Treatment in HIV Prevention and Care: Past Successes and Future Challenges David S. Metzger, Ph.D. University of Pennsylvania Center for Studies.

Drug Abuse Treatment in HIV Prevention and Care: Past Successes and Future Challenges David S. Metzger, Ph.D. University of Pennsylvania Center for Studies.

Similar presentations

Ads by Google